[Polaris Group] Announcement on the Change of Director at Subsidiary Lumosa Therapeutics
Lumosa Therapeutics, a subsidiary of Polaris Group, announced a change of director effective May 25, 2026. Mr. Chen Hong-wen has resigned, and Mr. Hou Yu-hsiang has been appointed as his successor, due to a reassignment by the parent company.
📋 Article Processing Timeline
- 📰 Published: May 25, 2026 at 09:00
- 🔍 Collected: May 26, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 26, 2026 at 09:10 (1h 10m after Collected)
1. Date of change: 2026/05/25
2. Personnel category: Natural person director
3. Former title and name: Chen Hong-wen, Director of Lumosa Therapeutics
4. Former resume: Director of Lumosa Therapeutics
5. New title and name: Hou Yu-hsiang, Director of Lumosa Therapeutics
6. New resume: HR Director of Lumosa Therapeutics
7. Circumstances of change: Resignation
8. Reason for change: Reassignment by the parent company
9. Number of shares held at the time of appointment: Not applicable
10. Former term: Not applicable
11. Effective date of new appointment: Not applicable
12. Change ratio of directors for the same term: Not applicable
13. Change ratio of independent directors for the same term: Not applicable
14. Change ratio of supervisors for the same term: Not applicable
15. Whether more than one-third of directors have changed: No
16. Other notes: The event does not qualify as a matter with significant impact on shareholder rights or securities prices under Article 7, Paragraph 6 of the Enforcement Rules of the Securities and Exchange Act.
2. Personnel category: Natural person director
3. Former title and name: Chen Hong-wen, Director of Lumosa Therapeutics
4. Former resume: Director of Lumosa Therapeutics
5. New title and name: Hou Yu-hsiang, Director of Lumosa Therapeutics
6. New resume: HR Director of Lumosa Therapeutics
7. Circumstances of change: Resignation
8. Reason for change: Reassignment by the parent company
9. Number of shares held at the time of appointment: Not applicable
10. Former term: Not applicable
11. Effective date of new appointment: Not applicable
12. Change ratio of directors for the same term: Not applicable
13. Change ratio of independent directors for the same term: Not applicable
14. Change ratio of supervisors for the same term: Not applicable
15. Whether more than one-third of directors have changed: No
16. Other notes: The event does not qualify as a matter with significant impact on shareholder rights or securities prices under Article 7, Paragraph 6 of the Enforcement Rules of the Securities and Exchange Act.
FAQ
Will this personnel change affect Lumosa Therapeutics' business?
The company has stated that this event does not significantly affect shareholder rights or security prices, suggesting no major operational change.
What is the background of the new director?
The new director is currently the HR director of Lumosa Therapeutics.